The US FDA recently approved four PARP suppressors, Olaparib, Rucaparib, Niraparib, and Talazoparib, for curing BRCA-mutated, HER2-negative advanced, metastatic ovarian, or breast cancer. This evidence concerns the gene PARP1 and breast carcinoma.